

BNSSG Shared Care Guidance

Please complete all sections

Section 1: Heading

Drug	Methylphenidate
Amber <i>three months</i>	
Indication	<p>Part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children and adolescents of 5* years of age and over:</p> <ul style="list-style-type: none"> • When remedial measures alone prove insufficient • Patient choice is taken into account <p>*Methylphenidate is licenced from 6 years, 'off-label' use for 5 year old patients, but supported by NICE Guideline (NG87; 1.5.13)</p>

Section 2: Treatment Schedule

Usual dose and frequency of administration <i>(Please indicate if this is licensed or unlicensed and any relevant dosing information)</i>	<p>Methylphenidate is a stimulant, whose treatment must be initiated under the supervision of a specialist in childhood behaviour disorders, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist.</p> <p>Differences in response between different modified release brands have been experienced. GPs should continue prescribing the brand that has been initiated by specialists, unless otherwise instructed.</p> <p>Xaggitin XL 18mg, 27mg, 36mg and 54mg tablets (Other brands available Concerta XL*, Xenidate XL and Delmosart) – Initially 18mg once daily, the dose may be adjusted in 18mg increments (dose interval of at least one week) to a maximum licensed dose of 54mg/day (maximum 2.1mg/kg) taken once daily in the morning. Xaggitin brand is considered first line.</p> <p>*Concerta XL under specialist supervision can be increased to a maximum of 108mg/day, maximum licensed dose remains 54mg/day.</p> <p>Equasym XL 10mg, 20mg, 30mg capsules Initially 10mg once daily in the morning before breakfast increasing if necessary by at least weekly increments of 5-10mg to a maximum licensed dose of 60mg daily (90mg daily (off-label) may be given under specialist supervision), maximum of 2.1mg/kg.</p> <p>Medikinet XL 5mg, 10mg, 20mg, 30mg, 40mg, 50mg and 60mg capsules Initially 10mg once daily in the morning before breakfast increasing if necessary by at least weekly increments to a maximum licenced dose</p>
--	---

BNSSG Shared Care Guidance

	<p>of 60mg daily (90mg daily (off-label) may be given under specialist supervision), maximum of 2.1mg/kg.</p> <p>Methylphenidate immediate release tablets Initially 5 mg 1-2 times a day, dose is increased if necessary at weekly intervals according to response, increased if necessary up to 60 mg daily in 2–3 divided doses (max licensed dose). 90mg daily in 2-3 divided doses (off-label) may be given under specialist supervision), maximum of 2.1mg/kg daily. If effect wears off in evening (with rebound hyperactivity) a dose at bedtime may be appropriate (establish need with trial bedtime dose).</p> <p>Methylphenidate is classed as a schedule 2 Controlled Drug under the Misuse of Drugs Regulations 2001 (MDR). Prescriptions must therefore conform to the MDR. It is 'best practice' and AWP procedure to prescribe one month supply or less of any schedule 2 controlled drugs at a time.</p>
<p>Route and formulation</p>	<p>Oral. Form dependent on manufacturer:</p> <ul style="list-style-type: none"> • 5mg, 10mg and 20mg Immediate release tablets • 18mg, 20mg, 27mg, 36mg, 54mg, XL/MR tablets • 5mg, 10mg, 20mg, 30mg, 40mg, 50mg and 60mg XL/MR capsules
<p>Duration of treatment</p>	<p>Methylphenidate should be continued for as long as it is effective.</p> <p>Discontinue if no response seen after 4-6 weeks of expected effective dose.</p>

Section 3: Monitoring

Please give details of any tests that are required before or during treatment, including frequency, responsibilities (please state whether they will be undertaken in primary or secondary care), cause for adjustment and when it is required to refer back to the specialist.

Baseline tests - where appropriate

Monitoring at baseline and during initiation is the responsibility of the specialist; once the patient is optimised on the chosen medicine, with no anticipated changes expected in the immediate future, prescribing will be transferred to the GP. Monitoring will remain with the specialist clinician in secondary care unless specific arrangements are made with GP. Patients will be reviewed by a specialist clinician annually as a minimum.

Baseline investigations include:

- Cardiovascular status including blood pressure, heart rate, height and weight on growth chart (see table below).
- Comprehensive history of concomitant medicines (past and present), co-morbid physical and psychiatric disorders or symptoms, and family history of sudden cardiac/unexplained death.
- Assessment of risk of diversion and/or misuse.

BNSSG Shared Care Guidance

Blood tests, ECG and other parameters are not required unless specifically indicated for individual patients.

Subsequent tests - where appropriate (*Please indicate who takes responsibility for taking bloods and interpreting results*)

Test	Frequency	Who by	Action/management For paediatric patients the use of a centile chart is recommended
Blood pressure (BP), pulse, weight, height	Prior to medication initiation	Initiating clinician (CAMHS* or Community Paediatrics department)	To prepare for medication titration
BP	After each dose increase, every 6 months and at annual review	CAMHS or Community Paediatrics department unless local arrangements have been made for individual patients (can also be managed by primary care under advice from secondary care)	Compare with normal range for age, if there is a clinically significant increase in blood pressure or systolic blood pressure is greater than 95 th percentile (measured on 2 occasions), refer to paediatric hypertension specialist; consider dose adjustment or alternative ADHD treatment.
Pulse			Compare with normal range for age. NICE guidance suggests to investigate a resting tachycardia of >120bpm; we suggest to monitor and possibly investigate a sustained resting tachycardia >100bpm; consider ECG; discuss with paediatric physical health colleagues as needed.
Height	Every 6 months		Plot height and weight of children and young people on a growth chart and ensure review by clinician responsible for treatment.
Weight	Children 10 years and under: 3 monthly		If there is evidence of significant weight loss or nil weight gain where expected, measure BMI and discuss with patient
	Children over 10 years and young people:		

BNSSG Shared Care Guidance

	<p>3 and 6 months following initiation and 6 monthly thereafter</p> <p><i>More often if concerns arise.</i></p>		<p>and family/ carer as appropriate.</p> <p>Strategies to manage weight loss include:</p> <ul style="list-style-type: none"> -Taking medication with or after food -Additional meals/snacks early morning or late evening when stimulant effects have worn off -Choosing high calorie foods of good nutritional value -Taking a planned break from treatment or changing medication. <p>Plot height and weight of children and young people on a growth chart and ensure review by clinician responsible for treatment.</p>
<p>Assessment of adherence and monitoring for effectiveness and adverse effects including suicidal ideation or behaviour, tics, sexual dysfunction, seizures and sleep.</p>	<p>After each dose adjustments, every 6 months, at annual review and as required based on the patient's needs and individual circumstances.</p>	<p>CAMHS or Community Paediatrics department unless local arrangements have been made for individual patients (can also be managed by primary care under advice from secondary care)</p>	<p>This should include a review of ADHD medication, including patient preferences, benefits, adverse effects, and ongoing clinical need. Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. If continuing medication, document rationale. Seek secondary care advice. With stimulant medication, this should include review of potential misuse and diversion.</p>

* Children and Adolescent Mental Health Service

BNSSG Shared Care Guidance

Section 4: Side Effects

Please list only the most pertinent side effects and management. Please provide guidance on when the GP should refer back to the specialist. For everything else, please see BNF or SPC.

Side effects and management	Side effect	Frequency	Action/management
	Headache	Very Common	Usually transient. If it is persistent, consider stopping and consult the specialist team
	Decreased Appetite	Very Common	Take medication after breakfast/food; Maximise food intake at times of least appetite suppression; increase snacking, introduce liquid calories (smoothies etc.)
	Dry Mouth	Very Common	Contact specialist if persists
	Insomnia	Very Common	This may be transient. Make sure medication is taken in the morning Refer to the specialist team if persistent
	CVS Symptoms: arrhythmias, tachycardia, hypertension, palpitations	Common	Monitor the BP, pulse, and if necessary perform an ECG. If the resting pulse is consistently >100bpm, contact the specialist team (consideration must be given to child/young person's age and what is expected for age)
	Agitation, anxiety, tremor, irritability, dizziness	Common	Common on initiation. Often subsides after several days. If no improvement, consult specialist
	Reduced libido, erectile dysfunction	Common	Contact specialist
	Dyspnoea	Common	Contact specialist if persists
	GI disorders – diarrhoea, constipation, nausea, vomiting, abdominal pain	Common	Contact specialist if persists
	Difficulties in visual accommodation	Rare	Usually transient. Optician to check to rule out other causes such as increased intraocular pressure. Contact specialist team if persistent
Serotonin Syndrome	Rare	Can occur when co-prescribed with antidepressants and lithium; stop methylphenidate immediately if suspected and seek expert advice. Early symptoms of serotonin syndrome include tachycardia, shivering, diarrhoea, diaphoresis, muscle cramps, agitation, and elevated body temperature	
Leukopenia, thrombocytopenia and anaemia	Rare	Refer to specialist team, medicine may need to be stopped	

BNSSG Shared Care Guidance

	<p>Effects on ability to drive and use machines Methylphenidate can cause dizziness, drowsiness and transient visual disturbances including difficulties with accommodation, diplopia and blurred vision (rare). It may have a moderate influence on the ability to drive and use machines. This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:</p> <ul style="list-style-type: none"> • The medicine is likely to affect your ability to drive • Do not drive until you know how the medicine affects you • It is an offence to drive while under the influence of this medicine • However, you would not be committing an offence (called 'statutory defence') if: <ul style="list-style-type: none"> ○ The medicine has been prescribed to treat a medical problem and ○ You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and ○ It was not affecting your ability to drive safely.
<p>Referral back to specialist</p>	<p>Contact specialist for advice if:</p> <ul style="list-style-type: none"> • There is a query regarding medication efficacy. • Patient finds the medication intolerable for any given reason. • If there is concern about observed mental/psychological or physical side effects (e.g. depression or hypertension). • If medication side effects persist despite intervention. • If patient is pregnant or breastfeeding

Section 5: Other Issues

(e.g. Drug Interactions, Contra-indications, Cautions, Special Recommendations)

Please list only the most pertinent action for GP to take (For full list please see BNF or SPC)

Issues	Significant Drug Interactions	
	MAOIs	E.g. moclobemide; risk of hypertensive crisis. Not to be given within 2 weeks of MAOIs.
	Volatile liquid anaesthetics	Increased risk of hypertension
	Tricyclic antidepressants	Increased levels of TCA as methylphenidate can inhibit metabolism
	Antipsychotics and other dopaminergic drugs	Methylphenidate increase extracellular dopamine levels thus may be associated with pharmacodynamic interactions when co-administered with dopamine antagonists or with direct and indirect dopamine agonists.
	Antihypertensives	Methylphenidate may reduce the effect of antihypertensives.
	Alcohol	Limited data, may increase CNS adverse reactions.
	Serotonergic drugs	Potential increased risk of serotonin syndrome with co-administration – monitor and discontinue methylphenidate as soon as possible if suspected.
	Clonidine	Serious adverse events including sudden death have been reported with concomitant use.
	Others	Not to be given with other sympathomimetics e.g. pseudoephedrine and decongestants.

BNSSG Shared Care Guidance

	<p>Contraindications</p> <ul style="list-style-type: none"> • Hypersensitivity to sympathomimetic amines or any of the excipients in the particular formulation • Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days after treatment (due to the risk of hypertensive crisis). • Hyperthyroidism or thyrotoxicosis • Agitated states • Advanced arteriosclerosis • Glaucoma • Pheochromocytoma <p><i>For patients with the following contraindications, methylphenidate can be prescribed under certain circumstances after a risk benefit consideration by the specialist has been taken into account:</i></p> <ul style="list-style-type: none"> • Pre-existing / symptomatic cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels) • Pre-existing cerebrovascular disorders cerebral aneurysm, vascular abnormalities including vasculitis or stroke or known risk factors for cerebrovascular disorders. • Diagnosis or history of recent severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder. • Diagnosis or history of severe and episodic (Type 1) Bipolar (affective) disorder <p>Special Warnings and precautions</p> <ul style="list-style-type: none"> • Tics – stimulants can exacerbate motor and phonic tics and Tourette’s Syndrome • Family history of Tourette’s syndrome • Aggression – stimulants may cause aggressive behaviour or hostility. • Seizures – stimulants may lower the seizure threshold. • Pregnancy – Seek specialist advice • Breast-feeding – Seek specialist advice • Anxiety <p>Dose reduction and discontinuation</p> <p>If paradoxical aggravation of symptoms or other serious adverse events occur, the dosage should be reduced or discontinued – advice should be sought from the specialist.</p> <p>Patients should be carefully monitored for the risk of diversion, misuse and abuse of Methylphenidate. Methylphenidate should be used with caution in patients with known drug or alcohol dependency because of a potential for abuse, misuse or diversion.</p>
<p>Reminder to ask patient about specific problems</p>	<p>Ask about emergence of any possible side effects/compliance to treatment issues.</p>

BNSSG Shared Care Guidance

Section 6: Advice to the patient

Advice for prescribing clinician to inform patient:

The patient and/or family/carer should be advised:

1. It is not advisable to drink alcohol, use recreational substances or consume excessive amounts of caffeine whilst taking Methylphenidate.
2. The patient should immediately report abdominal pain, unexplained nausea, malaise, darkening of the urine, jaundice, or suicidal thinking and/or self-harm to the GP.
3. Failure to attend annual reviews could result in the medication being stopped.
4. Patients can choose to try stopping the medication. Annual reviews are an ideal opportunity to discuss this but a desire to stop medication can be expressed and discussed at any time.
5. Information on drug prescribed including a patient information leaflet (PIL). Information on mental health conditions, treatments and medication can be found at:

[Choice and Medication](#)

NHS – [Attention Deficit Hyperactivity Disorder](#)

Methylphenidate [Patient Information Leaflet](#)

[Medicines for Children leaflet: Methylphenidate for ADHD](#)

Section 7: Generic principles of shared care for SECONDARY CARE

Please do not amend.

Core responsibilities

1. Initiating treatment and prescribing for the length of time specified in **section 1**.
2. Undertaking the clinical assessment and monitoring for the length of time specified in **section 1** and thereafter undertaking any ongoing monitoring as detailed in **section 3**.
3. Communicate details of the above in 1 and 2 to GP within the first month of treatment. This information should be transferred in a timely manner.
4. Communicate changes of medication form, strength or dose to the GP before the next repeat prescription is due (i.e. within 28 days). Note that a change of dose does not itself imply instability, and is usually done as a response to patient growth. If the secondary care clinician feels the medication is not at a stable dose, the GP will be informed that the secondary care provider will supply medication until this is again stable
5. Refer patients to GP and provide information of further action where appropriate e.g. if blood test is due.
6. To provide advice to primary care when appropriate, including queries about medication efficacy and side effects
7. Review concurrent medications for potential interaction prior to initiation of drug specified in **section 1**.
8. Stopping treatment where appropriate or providing advice on when to stop.
9. Reporting adverse events to the MHRA.
10. Reminder to ask patients about particular problems see **section 5**.

Section 8: Generic principles of shared care for PRIMARY CARE

Please do not amend.

Core responsibilities

1. Responsible for taking over prescribing after the length of time specified in **section 1**.
2. Responsible for any clinical assessment and monitoring if detailed in **section 3** after the length of time specified in **section 1**.
3. Review of any new concurrent medications for potential interactions.
4. Reporting adverse events to the MHRA.
5. Refer for advice to specialist where appropriate.
6. Reminder to ask patients about particular problems see **section 5**.

BNSSG Shared Care Guidance

Section 9: Contact Details

Name	Organisation	Telephone Number	E mail address
Initiating Clinician	AWP/ Sirona	As provided on correspondence	As provided on correspondence
Sarah Steel Highly Specialised Clinical Pharmacist	AWP	01249 474542	Sarah.steel6@nhs.net

Section 10: Document Details

Date prepared	28 th April 2023
Prepared by	Sarah Steel
Date approved by JFG	October 2023
Date of review	October 2026
Document Identification: Version	V3

Section 11: Collaboration

All shared care protocols should be BNSSG wide where possible. Specialists in any one discipline are encouraged to collaborate across the health community in preparing shared care guidance. Please give details

1. Sarah Steel - Highly Specialised Clinical Pharmacist, AWP
2. Samantha Hayer - CAMHS Consultant, AWP
3. Alfred Perrera - CAMHS Consultant, AWP
4. Richard Williams - Consultant Paediatrician, Sirona Care & Health
5. Richard Lee-Kelland - Consultant Community Paediatrician, Sirona Care & Health – from June 2023

Section 12: References

Please list references

1. NICE Guideline [\[NG87\]](#). Attention Deficit Hyperactivity Disorder: diagnosis and management. Updated 13.09.2019. Accessed Feb 2023.
2. SPC [Methylphenidate](#). Updated 11.11.2022. Accessed Feb 2023.
3. BNF Online. [Methylphenidate](#). Updated September 2022. Accessed Feb 2023.
4. Cortese S, *et al.* [Pharmacological and non-pharmacological interventions for adults with ADHD](#): protocol for a systematic review and network meta-analysis *BMJ Open*. Accessed May 2023.